Prezioso Elizabeth, Mancheski Eleanor, Shivok Kylee, Kaplan Zachary, Bowne Wilbur, Jain Aditi, Lavu Harish, Yeo Charles J, Nevler Avinoam
Sidney Kimmel Medical College, Philadelphia, PA 19107, USA.
Jefferson Pancreatic, Biliary and Related Cancer Center, Sidney Kimmel Cancer Center, Philadelphia, PA 19107, USA.
J Clin Med. 2024 Oct 17;13(20):6185. doi: 10.3390/jcm13206185.
: Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related deaths in the United States. Previous studies have indicated that microsatellite instability and deficient mismatch repair (MMR) may be associated with improved survival in patients with pancreatic cancer. Here, we aim to investigate the impact of deficient MMR (dMMR) status on oncologic outcomes in patients after resection of PDAC and periampullary adenocarcinoma. : This is a single-institution, retrospective study based on a prospectively maintained database. Pancreatic ductal adenocarcinoma (N = 342) and periampullary adenocarcinoma patients (N = 76) who underwent pancreatic resection surgery between 2016 and 2021 were included. Immunohistochemistry staining results of MMR proteins and next-generation sequencing data were recorded. Cancer-type dependent Cox regression analyses were performed to assess overall and disease-free survival, which was complemented with a 1:2 propensity-score matching for each of the cancer types in order to compare oncologic outcomes. : A total of 418 pancreatic cancer patients were included in the analysis. Fifteen patients (3.5%) were diagnosed as dMMR (PDAC N = 7 and periampullary adenocarcinoma N = 8). Cox regression modeling of dMMR status interaction with TNM staging and cancer type revealed that dMMR status strongly improves overall survival ( < 0.05). After propensity-score matching, Cox regression identified dMMR status as a significant marker of improved overall survival (HR = 0.27, 95%CI 0.09-0.88, = 0.029). : Overall, our findings suggest that dMMR status is associated with markedly improved survival outcomes in patients after resection of pancreatic and periampullary cancer. Future large-scale studies are needed to further validate this finding.
胰腺导管腺癌(PDAC)是美国癌症相关死亡的第三大主要原因。先前的研究表明,微卫星不稳定性和错配修复缺陷(MMR)可能与胰腺癌患者生存率的提高有关。在此,我们旨在研究错配修复缺陷(dMMR)状态对胰腺导管腺癌和壶腹周围腺癌切除术后患者肿瘤学结局的影响。
这是一项基于前瞻性维护数据库的单机构回顾性研究。纳入了2016年至2021年间接受胰腺切除术的胰腺导管腺癌患者(n = 342)和壶腹周围腺癌患者(n = 76)。记录了MMR蛋白的免疫组织化学染色结果和二代测序数据。进行了癌症类型相关的Cox回归分析以评估总生存期和无病生存期,并对每种癌症类型进行1:2倾向评分匹配以比较肿瘤学结局。
共有418例胰腺癌患者纳入分析。15例患者(3.5%)被诊断为dMMR(胰腺导管腺癌n = 7,壶腹周围腺癌n = 8)。dMMR状态与TNM分期和癌症类型相互作用的Cox回归模型显示,dMMR状态显著改善总生存期(P < 0.05)。倾向评分匹配后,Cox回归确定dMMR状态是总生存期改善的显著标志物(HR = 0.27,95%CI 0.09 - 0.88,P = 0.029)。
总体而言,我们的研究结果表明,dMMR状态与胰腺和壶腹周围癌切除术后患者的生存结局显著改善相关。未来需要大规模研究进一步验证这一发现。